Gene and Protein Expression Of MAGE, PD-L1 and Associated Immune Landscape Elements in Non-small Cell Lung Carcinoma, Urothelial Carcinoma, Squamous Cell Cancer Of The Head And Neck, and Cervical Carcinoma

Stephanie H. Astrow, Izak Faenza, Rajul J. Jain, Alexandra Drakaki, Wesley S. Chang, Clark C. Fjeld, Jin Li, and Adrian Bot

Kite, a Gilead company, Santa Monica, CA; University of California, Los Angeles, CA; Molecular MD, Portland, OR; Molecular MD, Cambridge, MA

CONCLUSIONS

• The results support clinical evaluation of a MAGE-A3/A6/TCR T-cell product across these major histologies.

• This 2-part MAGE-A3/A6 screening assay may reduce the potential for false-positive results obtained using the A6 TCR assay alone and be useful in screening patients for anti-MAGE-A3/TCR reactivity.

• Although the significance of the protein and gene expression patterns remains to be determined, the presence of PD-L1-positive tumor cells and immune cells in MAGE-A3/A6-positive tumors supports the concept of checkpoint blockade in combination with TCR therapy to treat advanced solid tumors.

REFERENCES


ACKNOWLEDGMENTS

Editorial support was provided by News in Global Science, LLC, funded by Kite, a Gilead company.

DISCLOSURES

SHA, AB: Employment with Kite, a Gilead company.
SA, ID: Employment and patent with Kite, a Gilead company.
KJ: Employment with Molecular MD, consultancy with Kite, a Gilead company; equity in Amgen and Seattle Genetics, GDF: Employment with Molecular MD, consultancy with Kite, a Gilead company.
JF: Employment with Molecular MD, consultancy with Kite, a Gilead company, equity ownership in Seattle Genetics.
ML: Employment with Molecular MD; consultancy with Kite, a Gilead company, equity ownership in Seattle Genetics.
DH, IF: None.

The statements made herein are the sole opinions of the authors and do not necessarily reflect the views of the National Cancer Institute or the National Institutes of Health.

POSTER 40

Gene and Protein Expression Of MAGE, PD-L1 and Associated Immune Landscape Elements in Non-small Cell Lung Carcinoma, Urothelial Carcinoma, Squamous Cell Cancer Of The Head And Neck, and Cervical Carcinoma

Stephanie H. Astrow, Izak Faenza, Rajul J. Jain, Alexandra Drakaki, Wesley S. Chang, Clark C. Fjeld, Jin Li, and Adrian Bot

Kite, a Gilead company, Santa Monica, CA; University of California, Los Angeles, CA; Molecular MD, Portland, OR; Molecular MD, Cambridge, MA

CONCLUSIONS

• The results support clinical evaluation of a MAGE-A3/A6/TCR T-cell product across these major histologies.

• This 2-part MAGE-A3/A6 screening assay may reduce the potential for false-positive results obtained using the A6 TCR assay alone and be useful in screening patients for anti-MAGE-A3/TCR reactivity.

• Although the significance of the protein and gene expression patterns remains to be determined, the presence of PD-L1-positive tumor cells and immune cells in MAGE-A3/A6-positive tumors supports the concept of checkpoint blockade in combination with TCR therapy to treat advanced solid tumors.

REFERENCES


ACKNOWLEDGMENTS

Editorial support was provided by News in Global Science, LLC, funded by Kite, a Gilead company.

DISCLOSURES

SHA, AB: Employment with Kite, a Gilead company.
SA, ID: Employment and patent with Kite, a Gilead company.
KJ: Employment with Molecular MD, consultancy with Kite, a Gilead company; equity in Amgen and Seattle Genetics, GDF: Employment with Molecular MD, consultancy with Kite, a Gilead company.
JF: Employment with Molecular MD, consultancy with Kite, a Gilead company.
ML: Employment with Molecular MD; consultancy with Kite, a Gilead company, equity ownership in Seattle Genetics.
DH, IF: None.

The statements made herein are the sole opinions of the authors and do not necessarily reflect the views of the National Cancer Institute or the National Institutes of Health.

POSTER 40

Gene and Protein Expression Of MAGE, PD-L1 and Associated Immune Landscape Elements in Non-small Cell Lung Carcinoma, Urothelial Carcinoma, Squamous Cell Cancer Of The Head And Neck, and Cervical Carcinoma

Stephanie H. Astrow, Izak Faenza, Rajul J. Jain, Alexandra Drakaki, Wesley S. Chang, Clark C. Fjeld, Jin Li, and Adrian Bot

Kite, a Gilead company, Santa Monica, CA; University of California, Los Angeles, CA; Molecular MD, Portland, OR; Molecular MD, Cambridge, MA

CONCLUSIONS

• The results support clinical evaluation of a MAGE-A3/A6/TCR T-cell product across these major histologies.

• This 2-part MAGE-A3/A6 screening assay may reduce the potential for false-positive results obtained using the A6 TCR assay alone and be useful in screening patients for anti-MAGE-A3/TCR reactivity.

• Although the significance of the protein and gene expression patterns remains to be determined, the presence of PD-L1-positive tumor cells and immune cells in MAGE-A3/A6-positive tumors supports the concept of checkpoint blockade in combination with TCR therapy to treat advanced solid tumors.

REFERENCES


ACKNOWLEDGMENTS

Editorial support was provided by News in Global Science, LLC, funded by Kite, a Gilead company.

DISCLOSURES

SHA, AB: Employment with Kite, a Gilead company.
SA, ID: Employment and patent with Kite, a Gilead company.
KJ: Employment with Molecular MD, consultancy with Kite, a Gilead company; equity in Amgen and Seattle Genetics, GDF: Employment with Molecular MD, consultancy with Kite, a Gilead company.
JF: Employment with Molecular MD, consultancy with Kite, a Gilead company.
ML: Employment with Molecular MD; consultancy with Kite, a Gilead company, equity ownership in Seattle Genetics.
DH, IF: None.

The statements made herein are the sole opinions of the authors and do not necessarily reflect the views of the National Cancer Institute or the National Institutes of Health.

POSTER 40

Gene and Protein Expression Of MAGE, PD-L1 and Associated Immune Landscape Elements in Non-small Cell Lung Carcinoma, Urothelial Carcinoma, Squamous Cell Cancer Of The Head And Neck, and Cervical Carcinoma

Stephanie H. Astrow, Izak Faenza, Rajul J. Jain, Alexandra Drakaki, Wesley S. Chang, Clark C. Fjeld, Jin Li, and Adrian Bot

Kite, a Gilead company, Santa Monica, CA; University of California, Los Angeles, CA; Molecular MD, Portland, OR; Molecular MD, Cambridge, MA

CONCLUSIONS

• The results support clinical evaluation of a MAGE-A3/A6/TCR T-cell product across these major histologies.

• This 2-part MAGE-A3/A6 screening assay may reduce the potential for false-positive results obtained using the A6 TCR assay alone and be useful in screening patients for anti-MAGE-A3/TCR reactivity.

• Although the significance of the protein and gene expression patterns remains to be determined, the presence of PD-L1-positive tumor cells and immune cells in MAGE-A3/A6-positive tumors supports the concept of checkpoint blockade in combination with TCR therapy to treat advanced solid tumors.

REFERENCES


ACKNOWLEDGMENTS

Editorial support was provided by News in Global Science, LLC, funded by Kite, a Gilead company.

DISCLOSURES

SHA, AB: Employment with Kite, a Gilead company.
SA, ID: Employment and patent with Kite, a Gilead company.
KJ: Employment with Molecular MD, consultancy with Kite, a Gilead company; equity in Amgen and Seattle Genetics, GDF: Employment with Molecular MD, consultancy with Kite, a Gilead company.
JF: Employment with Molecular MD, consultancy with Kite, a Gilead company.
ML: Employment with Molecular MD; consultancy with Kite, a Gilead company, equity ownership in Seattle Genetics.
DH, IF: None.

The statements made herein are the sole opinions of the authors and do not necessarily reflect the views of the National Cancer Institute or the National Institutes of Health.

POSTER 40

Gene and Protein Expression Of MAGE, PD-L1 and Associated Immune Landscape Elements in Non-small Cell Lung Carcinoma, Urothelial Carcinoma, Squamous Cell Cancer Of The Head And Neck, and Cervical Carcinoma

Stephanie H. Astrow, Izak Faenza, Rajul J. Jain, Alexandra Drakaki, Wesley S. Chang, Clark C. Fjeld, Jin Li, and Adrian Bot

Kite, a Gilead company, Santa Monica, CA; University of California, Los Angeles, CA; Molecular MD, Portland, OR; Molecular MD, Cambridge, MA

CONCLUSIONS

• The results support clinical evaluation of a MAGE-A3/A6/TCR T-cell product across these major histologies.

• This 2-part MAGE-A3/A6 screening assay may reduce the potential for false-positive results obtained using the A6 TCR assay alone and be useful in screening patients for anti-MAGE-A3/TCR reactivity.

• Although the significance of the protein and gene expression patterns remains to be determined, the presence of PD-L1-positive tumor cells and immune cells in MAGE-A3/A6-positive tumors supports the concept of checkpoint blockade in combination with TCR therapy to treat advanced solid tumors.

REFERENCES


ACKNOWLEDGMENTS

Editorial support was provided by News in Global Science, LLC, funded by Kite, a Gilead company.

DISCLOSURES

SHA, AB: Employment with Kite, a Gilead company.
SA, ID: Employment and patent with Kite, a Gilead company.
KJ: Employment with Molecular MD, consultancy with Kite, a Gilead company; equity in Amgen and Seattle Genetics, GDF: Employment with Molecular MD, consultancy with Kite, a Gilead company.
JF: Employment with Molecular MD, consultancy with Kite, a Gilead company.
ML: Employment with Molecular MD; consultancy with Kite, a Gilead company, equity ownership in Seattle Genetics.
DH, IF: None.

The statements made herein are the sole opinions of the authors and do not necessarily reflect the views of the National Cancer Institute or the National Institutes of Health.